• ScreenPro (SCRN) will now offer concierge medical services providing home visit care beginning July 12
  • The services include medical advisory, preventive screening and corporate wellness and executive health
  • The program will begin in Vancouver with potential for future expansion
  • ScreenPro Security is a medical technology company that provides testing solutions across Canada
  • ScreenPro (SCRN) is up by 16.67 per cent and is currently trading at $0.035 per share

ScreenPro (SCRN) will now offer concierge medical services providing home visit care beginning July 12.

The program enlists accredited physicians and nurses to provide medical advisory, corporate wellness and executive health, and preventive screenings to determine the presence or absence of disease. 

The program will begin in Vancouver with potential for future expansion.

Patients will benefit from same-day appointments and direct email and phone contact with physicians.

ScreenPro’s target audience will have an initial focus on executives and corporations with large staff to keep costs low and allow for scalability.

Andrew Ryu, ScreenPro’s CEO, commented,

“When you think about the health care space in Canada in 2019 being worth $265.5 billion, and with the overall health spending representing 11.5 per cent of Canada’s gross domestic product, that is a really interesting market. We are building a health care business that has sustainability and longevity and that will add recurring high-margin revenue metrics to our existing business model.”

ScreenPro Security is a medical technology company that provides testing solutions across Canada. 

ScreenPro (SCRN) is up by 16.67 per cent and is currently trading at $0.035 per share as of 9:30 am ET.

More From The Market Online

Canadian biotech stock investigates potential weight loss drugs

FSD Pharma Inc. (CSE:HUGE) is expanding its pipeline into metabolic and related disorders including weight loss and liver health.
The Market Online Video

Emerging opportunity in a growing, high-value dermatological market

Kane Biotech (TSXV:KNE) engages in the development and commercialization of products that prevent and remove microbial biofilms.